1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Lagis Enterprise Co., Ltd.

Lagis Enterprise Co., Ltd.

TTPEX:6730
31.80
TWD
-0.95
(-2.90%)
1.97EPS
18.99P/E
1.38BMarket Cap
Lagis Enterprise Co., Ltd.
TPEX:6730
(Taipei Exchange)

Recent

price

31.80

P/E

ratio

18.99

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.84
13.33
12.93
13.04
9.98
12.28
13.82
14.37
14.2
15.08
14.34
Revenue per Share
2.66
2.81
2.78
2.86
1.01
1.53
2.22
2
2.13
2.14
2
Basic EPS, GAAP
2.78
3.14
3.05
3.17
0.39
2.09
0.45
-4.64
-6.31
1.23
2.33
Free Cash Flow per Basic Share
1.63
1.62
1.5
1.62
1.43
0.8
1
1.8
1
0.99
- -
Dividend per Share
10.13
11.17
12.41
15.16
14.75
15.47
16.7
16.9
18.07
20.99
20.38
Book Value per Share
10.1
11.15
12.38
15.14
14.67
15.32
16.51
16.73
17.98
20.93
20.34
Tangible Book Value per Share
25
28
31
31
32
32
32
32
32
32
34
Basic Weighted Avg Shares
353
374
399
407
319
393
442
460
454
488
492
Sales/Revenue/Turnover
23.6
25.12
26.24
27.63
13.97
16.49
18.47
16.76
17.87
18.02
16.54
Operating Margin (%)
33
30
25
29
27
31
32
32
32
43
54
Depreciation Expense
68
79
86
89
32
49
71
64
68
69
69
Net Income, GAAP
16.71
17.01
19.71
20
19.99
20.01
19.81
20
20
20
20
Effective Tax Rate (%)
19.25
21.07
21.54
21.93
10.12
12.45
16.06
13.94
15.02
14.2
13.95
Profit Margin (%)
94
102
117
209
202
223
219
157
167
188
158
Working Capital
71
26
- -
1
- -
5
3
155
377
255
243
LT Debt
324
357
397
485
472
495
534
541
580
762
740
Total Equity
- -
21.91
19.91
19.3
7.26
10.41
12.25
9.63
7.6
6.91
6.56
Return on Invested Capital (%)
- -
19.77
20.99
19.71
6.74
10.01
13.57
10.17
8.07
7.14
7.31
Return on Capital (%)
- -
23.11
22.77
20.21
6.75
10.12
13.8
11.93
12.18
10.32
10.41
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
14
20
LT Borrowings
255
251
243
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
1,285
1,307
1,379

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
310
320
342
Cash, Cash Equivalents & STI
95
100
114
Accounts Receivable, Net
50
45
51
Inventories
123
127
127
Total Current Liabilities
122
169
185
Payables & Accruals
- -
- -
- -
ST Debt
12
14
20
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.54%
31.42%
Free Cash Flow
- -
-171.83%
-119.62%
Net Income, GAAP
- -
18.95%
1.51%
Sales/Revenue/Turnover
- -
9.14%
7.33%
Total Cash Common Dividend
- -
3.36%
0.25%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
113
116
118
107
454
2025
116
122
126
124
488
2026
115
127
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
0.55
0.49
0.49
2.13
2025
0.54
0.48
0.64
0.49
2.14
2026
0.44
0.45
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.99
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Lagis Enterprise Co., Ltd. specializes in the development and manufacturing of minimally invasive surgical instruments and devices. The company's core product portfolio includes laparoscopic consumables, endoscopic instruments, trocar systems, single-port access devices, bipolar forceps, suction irrigation systems, specimen retrieval bags, wound protectors, and gynecological surgical instruments such as uterine manipulators and advanced single-port devices for vNOTES (vaginal natural orifice transluminal endoscopic surgery). Lagis operates with a strong focus on medical equipment manufacturing, targeting surgical and healthcare providers across more than 50 countries globally, including Asia, America, Europe, Oceania, and Africa. Founded in 2004 and headquartered in Taichung, Taiwan, Lagis is recognized as Asia's leading MDR qualification brand with products made in Taiwan that emphasize high precision and durability. Recently, Lagis has significantly expanded its production capacity by completing a second factory facility in Taiwan, which is three times larger than its original plant and is currently undergoing GMP certification. The company has strengthened its position in the minimally invasive surgical device market by leveraging advanced automation in production to optimize quality and efficiency. Lagis maintains a strategic emphasis on innovation in robotic surgery applications, notably enhancing its suction irrigation system with FDA 510(k) clearance for improved performance in such surgeries. The company also continues to promote partnerships and participate in international medical expos to bolster its global footprint and customer reach in the healthcare sector. These operational expansions and product advancements mark key developments for Lagis in the last 1-2 years, reinforcing its leadership in minimally invasive surgical solutions. Lagis Enterprise Co., Ltd. reports consistent financial performance backed by a diversified portfolio, reinforcing its strategic focus on expanding minimally invasive surgical devices and enhancing manufacturing capacities to meet growing global demand. The company remains privately held with ongoing commitments to research, development, and automation technology in surgical instruments manufacturing. This comprehensive profile reflects Lagis Enterprise's position as a specialized medical device manufacturer delivering advanced laparoscopic and endoscopic solutions worldwide with recent expansions and innovations to support surgical precision and patient outcomes.